News

ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients

Peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) published in the New England Journal of Medicine showed that baricitinib in combination with remdesivir reduces recovery time, improves clinical status and demonstrates a trend towards a decrease in mortality  in hospitalised COVID-19 patients with pneumonia.

Those who took both drugs had a median time to recovery of seven days, compared with eight days for those who took only remdesivir. But for people who were on the edge of requiring invasive ventilation, median recovery time fell from 18 days on remdesivir alone to 10 days on both drugs.

This publication follows November’s announcement that baricitinib, first identified as a potential treatment by the BenevolentAI team in February, was granted Emergency Use Authorisation (EUA) by the U.S. Food and Drug Administration (FDA) for use in hospitalised COVID-19 patients who require supplemental oxygen or invasive mechanical ventilation. This latest data further supports the FDA’s decision to issue a EUA, again validating our AI-derived hypothesis for baricitinib as a COVID-19 treatment option. 

The urgency of the pandemic heightened the need to identify therapeutic options for patients suffering from severe symptoms of COVID-19. In the last week of January, our CEO, Joanna Shields, asked our team how we could best leverage our technology to combat this public health emergency. Our scientists were a step ahead and were already using the Benevolent Platform® to investigate options.

Following our discovery and scientific collaboration with Eli Lilly, baricitinib was dosed in patients in an unprecedented time frame. While vaccines and mass immunisations will be key to curbing the spread of COVID-19, therapeutic options for infected patients will continue to be crucial in reducing morbidity and mortality from this deadly virus. 

Baricitinib is a rheumatoid arthritis drug, owned and marketed by Eli Lilly under the brand name Olumiant™ and is now available as a treatment for hospitalised COVID-19 patients under EUA.


More Posts

You Might Also Like

News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021